Peter Geschek
Long only

Tiny Esperion Takes On Industry Giants In Battle To Find The Next Lipitor

Esperion (NASDAQ:ESPR) is a small company developing a cholesterol drug with the aim to succeed Lipitor or at least to complement it. It is facing up to pharma giants like Sanofi, Amgen and Pfizer. But the company has one asset that nobody else does: its executive chairman is the one and only Roger Newton, an icon of the cholesterol business.

In September Esperion announced positive top-line results from a Phase 2a study of its drug, ETC-1002 when added to statin therapy in patients with elevated levels of low density LDL-C or "bad cholesterol".

Later in 2013 Esperion is planning a larger Phase 2b trial targeting the statins intolerant population with results expected in 2014.

Roger Newton

The legendary...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details